-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Beta Bionics, Raises Price Target to $24

Benzinga·10/28/2026 15:51:03
Listen to the news
Piper Sandler analyst Matt O'Brien reiterates Beta Bionics (NASDAQ:BBNX) with a Overweight and raises the price target from $20 to $24.